xxixPharmacogenetics to Reduce the Cost Incurred
by Adverse Drug Reactions .................................................................. 688
Cost Effectiveness of HIV Genotyping in Treatment of AIDS ............. 689
Cost-Effectiveness of Warfarin Pharmacogenomics ............................. 690
Cost-Benefi t Analysis of KRAS and BRAF Screening in CRC ........... 690
Lowering the High Costs of Cancer Chemotherapy ............................. 691
Concluding Remarks on the Economics of Personalized Medicine ......... 691
References ................................................................................................. 69224 Future of Personalized Medicine ........................................................... 693
Introduction ............................................................................................... 693
Ongoing Studies ........................................................................................ 693
Personal Genome Project ...................................................................... 693
Genome-Wide Association Studies ....................................................... 694
The 1000 Genomes Project ................................................................... 695
Genomics of Aging in a Genetically Homogeneous Population .......... 696
Translational Science and Personalized Medicine ................................ 696
Translation of Genomic Research into Genetic
Testing for Healthcare ........................................................................... 697
Long-Term Behavioral Effects of Personal Genetic Testing ................ 698
Personalized Predictive Medicine ......................................................... 698
Connected Health and Personalized Medicine ..................................... 699
Drivers for the Development of Personalized Medicine ........................... 699
Evolution of Medicine as a Driver for Personalized
Therapy Markets ................................................................................... 699
Collaboration Between the Industry and the Academia ............................ 700
Opportunities and Challenges of Personalized Medicine ......................... 701
Prospects and Limitations of Genetic Testing ....................................... 701
Genetic Testing and Concerns About Equality of Healthcare ............... 703
Pharmacotyping .................................................................................... 703
Comparative-Effectiveness Research and Personalized Medicine ........... 704
Medicine in the Year 2025 ........................................................................ 704
Concluding Remarks About the Future of Personalized Medicine ........... 706
References ................................................................................................. 708
Index ................................................................................................................. 709
Contents